The availability of new, innovative and specialist cancer drugs in Australia, with particular reference to:

1. the timing and affordability of access for patients; 
2. the operation of the Pharmaceutical Benefits Advisory Committee and the Pharmaceutical Benefits Scheme in relation to such drugs, including the impact of delays in the approvals process for Australian patients; 
3. the impact on the quality of care available to cancer patients; and 
4. any related matters.